What is this paper about
This paper shows that statins remain one of the strongest cardiovascular therapies, consistently linked to fewer major events and lower mortality across very large populations, but not without trade-offs such as diabetes risk, muscle symptoms, and rises in lipoprotein(a). The full paper is worth reading because it shows where the benefit is most convincing, where the risks matter most, and how to think more clearly about the real balance between protection and harm.
